Mediolanum International Funds Ltd Purchases 82,402 Shares of Gilead Sciences, Inc. $GILD

21 Nov 2025, 14:24 by Danessa Lincoln · The Markets Daily

Mediolanum International Funds Ltd boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 84.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 179,832 shares of the biopharmaceutical company’s stock after acquiring an additional 82,402 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Gilead Sciences were worth $19,902,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in GILD. One Wealth Advisors LLC grew its stake in Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after buying an additional 2,364 shares during the last quarter. Ariel Investments LLC grew its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Simplify Asset Management Inc. increased its stake in shares of Gilead Sciences by 148.6% in the second quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock worth $5,864,000 after purchasing an additional 31,618 shares during the period. Sivik Global Healthcare LLC lifted its position in shares of Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Wealth Management Associates Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at approximately $255,000. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GILD shares. Argus increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Finally, The Goldman Sachs Group upped their price target on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.45.

View Our Latest Analysis on GILD

Gilead Sciences Stock Down 2.4%

GILD opened at $124.99 on Friday. The firm has a market cap of $155.07 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm’s 50-day simple moving average is $118.23 and its 200-day simple moving average is $113.37. Gilead Sciences, Inc. has a twelve month low of $88.07 and a twelve month high of $128.70.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm earned $2.02 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 125,146 shares of company stock worth $15,148,441. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

(Free Report)